Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | VHL | P40337 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 4/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19791266 | 0.83 | VHL (0.44) | MEN1KMT2AVHLALDH1A1HCAR2 | |
| SCHEMBL18994354 | 0.83 | MEN1 (0.43) | MEN1KMT2AVHLALDH1A1HCAR2 | |
| SCHEMBL12384314 | 0.79 | MEN1 (0.43) | MEN1KMT2AVHLALDH1A1HCAR2 | |
| SCHEMBL21324929 | 0.78 | MAPK14 (0.37) | SMN1; SMN2 | |
| SCHEMBL12594197 | 0.78 | CHRM1 (0.33) | SMN1; SMN2 | |
| SCHEMBL19399866 | 0.77 | — | — | |
| SCHEMBL2797767 | 0.77 | — | — | |
| SCHEMBL15925052 | 0.77 | ESR1 (0.34) | — | |
| SCHEMBL13028951 | 0.75 | CHRM1 (0.39) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16275992 | 0.75 | NR1I2 (0.40) | MEN1KMT2AVHLALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | US | disclosed |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210017169-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| US-20200392113-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180111941-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20100323887-A1 | MESOIONIC PESTICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323887-A1 | MESOIONIC PESTICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | MEN1 2346/4885KMT2A 32/4885VHL 494/4885 |
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MEN1 4833/4885KMT2A 2341/4885VHL 3011/4885 |
| US-20210017169-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MEN1 4833/4885KMT2A 2341/4885VHL 3011/4885 |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | MEN1 4221/4885KMT2A 3171/4885VHL 1079/4885 |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | MEN1 1036/4885KMT2A 556/4885VHL 528/4885 |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | MEN1 4849/4885KMT2A 2767/4885VHL 2575/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | MEN1 1411/4885KMT2A 1568/4885VHL 4661/4885 |
| US-20200392113-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MEN1 4849/4885KMT2A 2767/4885VHL 2575/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | MEN1 188/4885KMT2A 736/4885VHL 37/4885 |
| US-20100323887-A1 | MESOIONIC PESTICIDES | DDT, CHRM1, CHRM3 | MEN1 255/4885KMT2A 3136/4885VHL 4858/4885 |
| US-11530210-B2 | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | MEN1 4833/4885KMT2A 2341/4885VHL 3011/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MEN1 1500/4885KMT2A 2809/4885VHL 547/4885 |
| US-20180111941-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | MEN1 776/4885KMT2A 462/4885VHL 4469/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | MEN1 298/4885KMT2A 1997/4885VHL 174/4885 |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | MEN1 4224/4885KMT2A 653/4885VHL 6/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | MEN1 2563/4885KMT2A 2222/4885VHL 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.